New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix’s RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy
Research Reveals Reduction in Hospitalization Rates, Length of Stay and Health Care Costs When Treating OIC with FDA-Approved Prescription Medications LAVAL, QC, March 24, 2022 — Bausch Health Companies Inc. (NYSE/TSX: BHC)…